Reducing Postoperative Ocular Infection CME Info

Sponsorship Statement:
This continuing medical education activity is jointly sponsored by and

Support Statement:
This activity is supported by an educational grant from Bausch + Lomb.

Title:
Reducing Postoperative Ocular Infection and Inflammation: Strategies for Success

Learning Objectives:
At the conclusion of this activity participants should be able to:

• Analyze recent epidemiologic studies of changing susceptibility among pathogens encountered in routine ocular care and describe new anti-infective strategies for treatment
• Analyze preoperative, perioperative and postoperative use of antibiotic prophylaxis for the prevention of endophthalmitis.
• Discuss the rationale for preoperative use of antibiotics and anti-inflammatories to treat the ocular surface and decrease the risk of cystoid macular edema (CME).

Course Chair:
Richard L. Lindstrom, MD
Chief Medical Editor
OCULAR SURGERY NEWS
Adjunct Professor Emeritus
University of Minnesota Department of Ophthalmology
Founder and Attending Surgeon
Minnesota Eye Consultants, PA
Minneapolis, Minnesota

Faculty:
Penny A. Asbell, MD, FACS, MBA
Section Editor, Contact Lenses
OCULAR SURGERY NEWS
Professor of Ophthalmology
Mount Sinai Medical Center
New York, New York

Terrence P. O'Brien, MD
Editorial Board Member
OCULAR SURGERY NEWS
Charlotte Breyer Rodgers Distinguished Chair in Ophthalmology
Director, Refractive Surgery Service
Bascom Palmer Eye Institute
Palm Beach, Florida

Continuing Medical Education Information:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of OCULAR SURGERY NEWS^® and Vindico Medical Education. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Vindico Medical Education designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit ^tm. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January XX, 2011 to January XX, 2012

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the Pre-test questions, watch the lectures, complete the CME Post-test, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the Post-test questions correctly. Upon receipt of the completed materials, if a satisfactory score on the Post test is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)^tm certificate.

Faculty:
Richard L. Lindstrom, MD
Penny A. Asbell, MD, FACS, MBA
Terrence P. O'Brien, MD

External Reviewer:
Terry Kim, MD

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Faculty members report the following relationship(s):

Richard L. Lindstrom, MD
Consultant: Acufocus, Inc., Abbott Medical Optics, Inc, Adoptics, Advanced Refractive Technologies, Alcon Laboratories, Inc, AqueSys, Bausch + Lomb, Inc, Bio Syntrx, Bradley Scott, Inc, Calhoun Vision Inc, Clarity Ophthalmics, Clear Sight, CoDa Therapeutics, EBV Partners, EGG Basket Ventures, Elenza, Encore, Evision Photography, Eyemaginations Inc, ForSight, ForeSight Venture Fund #3, Glaukos Corporation, High Performance Optics, Hoya Surgical Optics, Improve Your Vision, OcularTherapeutix, Lensar, LenSx, Lifeguard Health, Lumineyes, Inc, Minnesota Eye Consultants, P.A., NuLens, Ocular Surgery News/Slack, Ocular Optics, Omega Eye Health, Omeros Corp, Pixel Optics, Quest, Refractec, Revital Vision, Seros Medical, LLC, Sight Path, Surgijet/Visijet, 3D Vision Systems, TLC Vision, Tearlabs, Inc, Tracey Technologies, Transcend Medical Inc, True Vision, Versant, Vision Solutions Technologies
Investor: Acufocus, Inc., Abbott Medical Optics, Inc;, AqueSys, Bausch + Lomb, Inc, , Bio Syntrx, Bradley Scott, Inc, Calhoun Vision Inc, Clarity Ophthalmics, Clear Sight, CoDa Therapeutics, Confluence Acquisition Partners I, Inc, EBV Partners, EGG Basket Ventures, Encore, Evision Photography, Evision Medical Laser, ForeSight Venture Fund #3, Fziomed, Glaukos Corporation, HEAVEN Fund, Healthcare Transaction Services, High Performance Optics, Improve Your Vision, OcularTherapeutix, Lensar, LenSx, Lifeguard Health, Minnesota Eye Consultants, P.A., Nisco, NuLens, Ocular Optics, Omega Eye Health, OnPoint, Pixel Optics, Quest, Rainwater Healthcare, Refractec, Revision Optics, Revital Vision, SarboxNP, Schroder Life Science Venture Fund, Sight Path, Solbeam, 3D Vision Systems, TLC Vision, Tearlabs, Inc,, Tracey Technologies, Transcend Medical Inc, True Vision, Viradax, Vision Solutions Technologies, TriPrima, Wavefront Systems
Medical Director: Refractec, Sight Path, TLC Vision,
Royalty: Acufocus, Inc., Bausch + Lomb, Inc, Quest

Penny A. Asbell, MD, FACS, MBA
Consulting Fees: Pfizer
Fees for Non-CME Services: Alcon Laboratories, Inc., Bausch + Lomb, Santen, Vistakon Pharma
Contracted Research: Alcon Laboratories, Inc.

Terrence P. O’Brien, MD
Consulting Fees: Alcon Laboratories, Inc, Allergan, AMO/VISX/ABBOTT, Bausch + Lomb, Inspire, ISTA, Santen, Vistakon

External reviewer reports the following relationship(s):
Terry Kim, MD
Consulting Fees: Alcon Laboratories, Inc, Allergan, Inspire, ISTA Pharmaceuticals, Pfizer

OCULAR SURGERY NEWS and Vindico staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Overview:
Prophylactic treatment of the ocular surface with anti-inflammatory and anti-infective agents can enable faster recovery from surgical procedures while preventing painful and potentially devastating infections. In this symposium, the rationale for prophylactic treatment, data on increasing resistance developing among organisms that cause ocular infection and how this will affect anti-infective selections will be discussed, and leading clinicians will explain their approaches to clinical challenges in interactive case presentations.

Target Audience:
The intended audience for this activity is ophthalmologists and other healthcare professionals involved in the treatment of ocular infection and inflammation.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:
Created and published by Slack Incorpoated^®, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Printed in the USA. Copyright^© 2010 Slack Incorporated^®. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and OCULAR SURGERY NEWS^® continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and OCULAR SURGERY NEWS^®. Neither Vindico Medical Education, OCULAR SURGERY NEWS^®, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.